Christian Kowol studied chemistry at the University of Vienna. Having defended his doctoral thesis in 2009, he held Post Doc positions at the Institute of Inorganic Chemistry, the Institute of Cancer Research at the Medical University of Vienna, and the Technical University of Lisbon. His research focus lies on the synthesis of novel anticancer drugs with increased activity and tolerability, especially in the field of “prodrugs” (agents selectively activated within the tumor) as well as targeted transport to the tumor.
He is co-founder of the start-up „P4 Therapeutics“, which aims at developing his most promising platinum-based compound “Albuplatin” into the clinic.
Christian Kowol was promoted to Associate Professor in May 2020.
